The mechanism behind the spatiotemporal control of cancer cell dynamics and its possible association with cell proliferation has not been well established. By exploiting the intravital imaging technique, we found that cancer cell motility and invasive properties were closely associated with the cell cycle. In vivo inoculation of human colon cancer cells bearing fluorescence ubiquitination-based cell cycle indicator (Fucci) demonstrated an unexpected phenomenon: S/G2/M cells were more motile and invasive than G1 cells. Microarray analyses showed that Arhgap11a, an uncharacterized Rho GTPaseactivating protein (RhoGAP), was expressed in a cell-cycle-dependent fashion. Expression of ARHGAP11A in cancer cells suppressed RhoA-dependent mechanisms, such as stress fiber formation and focal adhesion, which made the cells more prone to migrate. We also demonstrated that RhoA suppression by ARHGAP11A induced augmentation of relative Rac1 activity, leading to an increase in the invasive properties. RNAi-based inhibition of Arhgap11a reduced the invasion and in vivo expansion of cancers. Additionally, analysis of human specimens showed the significant up-regulation of Arhgap11a in colon cancers, which was correlated with clinical invasion status. The present study suggests that ARHGAP11A, a cell cycledependent RhoGAP, is a critical regulator of cancer cell mobility and is thus a promising therapeutic target in invasive cancers.
Introduction
Unlimited expansion due to unchecked cell cycle progression and increased penetration into the normal neighboring environment is a formidable and life-threatening aspect of cancer cells. In fact, cell cycle regulation has been a major research topic in the field of cancer cell biology.
In addition, cancer has highly dynamic properties, including invasion of surrounding tissues, infiltration of the systemic circulation, and pioneering of a new 'niche' for colonization far from its origin [1, 2] . Although factors determining cancer cell mobilization, such as Rho family small G proteins, have been extensively studied [3] , the association between cell cycle regulation and cellular mobility of cancer cells remains unclear. To elucidate this dynamic interaction it would be valuable to observe the spatiotemporal properties of cell cycle regulation and cell mobility simultaneously in vivo.
Recently, intravital multiphoton microscopy was employed for dissecting intact cellular phenomena in various biological systems, such as the immune response [4, 5] , inflammatory reactions [6] , and bone remodeling [7] . This advanced imaging technique has enabled us to grasp the dynamic behaviors of living cells in tissues and organs. Cancer cells are also highly mobile and their migratory behaviors have been evaluated using this imaging technique [8] [9] [10] , although its correlation with the proliferative nature of cells remains elusive.
Here, we succeeded in visualizing dynamic events during cancer cell invasion and metastasis by using intravital multiphoton microscopy. By means of fluorescent ubiquitination-based cell cycle indicator (Fucci), a special fluorescent protein probe used for monitoring the cell cycle in live cells, we identified a close association between the cell cycle and the mobilizing properties of cancer cells.
Results

Dynamic visualization detects cell cycle-associated cancer cell mobilization and invasion in vivo
We utilized intravital multiphoton microscopy and Fucci technology [11] to study the cell cycle and migration in a living system. In this Fucci system, Geminin (GMNN), a nuclear protein enriched in the S/G2/M phases, and Cdt1, enriched in the G1 phase, were respectively marked with green-and redfluorescent proteins ( Figure 1A , upper panel). Fucci-expressing HCT116 human invasive colon cancer cells ( Figure 1A , lower panel) were inoculated into the cecum or subcutaneous tissues of an immunocompromised NOD/SCID mouse [12] [13] [14] . Fourweeks after implantation, tumors were observed intravitally. We preferentially detected S/G2/M-phase Fucci-green cells along the marginal areas of cancer invasion heads after inoculated into the cecum wall ( Figure 1B ). Similar distributional changes in Fucci-green and -red cells were detected when the cancer cells were inoculated into the mesentery or colon wall ( Figure S1 ). The preferential distribution of cancer cells in the S/G2/M phases was also observed in surgically resected human colon cancer samples ( Figure S2 ). Cancer cells at invasion heads were preferentially stained with antibodies against GMNN [15, 16] compared with those in non-tumor regions or the tumor centers.
Next, we examined the dynamic nature of cancer cells in vivo. Fucci-expressing HCT116 cancer cells were highly mobile upon inoculation into subcutaneous tissues, and some cancer cells were actively invading, appearing to 'dive' into the surrounding interstitium during imaging time-courses ( Figure 1C ; Movie S1). Notably, almost all of the diving cells were green ( Figure 1C , arrowheads), suggesting that cancer cell motility and invasion might be dependent on the cell cycle. Moreover, we could detect their migratory movements during extravasation for metastasis ( Figure 1D ; Movie S2). Some cells were found to migrate out from cancer cell aggregates stuck within blood vessels, and these were also all green. A certain period of observation (for up to 2 h) of tumor central regions resulted in capture of basal sluggish behaviors, as well as streaming movement with blood flow, of various cancer cell types, which allowed us to image a sufficient number of cells for quantification ( Figure 1D ; Movie S3). Detailed statistical analyses of cell tracking velocity clearly demonstrated that green cancer cells (in the S/G2/M phase) have significantly higher motility than red G1 cells (mean tracking velocity 1.3960.08 mm/min for Fucci-green vs. 1.0960.06 mm/min for Fucci-red; p = 0.00191) ( Figure 1E ). We confirmed that a certain period of intravital imaging (up to 3 h) did not affect the mobility of cancer cells ( Figure S3 ). By tracking individual cells over a period of time, we excluded the possibility that such mobility change in the S/G2/M phases reflected the motion regarding cytokinesis. These results indicate that certain molecules preferentially expressed in the S/G2/M Fucci-green phases facilitate the migration and invasion of cancer cells.
Identification of ARHGAP11A as a cell cycle-dependent mobility-controlling molecule
To elucidate the molecular basis of the control of cell cycledependent motility, we performed cDNA microarray-based comparative analyses among Fucci-green and -red cells cultured in vivo (Figure 2A ). In the microarray analysis, 2,032 probes (1,656 genes) showed .two fold changes in expression ( Figure 2B ; Table S1 ). As anticipated, most of these genes encode proteins associated with cell division and mitosis. Based on gene ontology categories, we extracted genes related to cellular movement from the 1,656 candidates and found that an uncharacterized Rho GTPase-activating protein (RhoGAP), Arhgap11a, was preferentially expressed in green S/G2/M phase cancer cells ( Figure 2B , Table S1 ). All of the three probes for Arhgap11a gene were highly ranked (5th, 12th, and 41st) among the 2,023 probes. It has been demonstrated that Rho family small G proteins such as Rho, Rac, and Cdc42, and their regulatory molecules, such as RhoGAP, cooperatively control cellular motility in both normal and cancer cells [17] [18] [19] [20] [21] . The preferential expression of Arhgap11a in Fucci-green cells was confirmed at both the mRNA ( Figure 2C ) and protein levels ( Figure 2D ). Additionally, we demonstrated a time-dependent gradual increase in Arhgap11a expression during progression through the cell cycle from G1 to S/G2/M ( Figure 2E ; Figure S4 ), strengthening the concept that Arhgap11a expression is controlled in a cell cycle progressiondependent manner. Cell cycle-dependent expression of Arhgap11a was also detected in other colon cancer cell lines besides HCT116, such as DLD1, HT29 and KM125M ( Figure 2F ) and HeLa ( Figure S5 ) as well as in non-cancer cell lines such as HEK293 cells ( Figure S6 ), suggesting the presence of a general mechanism for this characteristic expression regulation of Arhgap11a in many cell types. To elucidate the mechanism underlying the cell cycle-dependent expression of Arhgap11a, we further examined the transcriptional control of this gene. E2F family transcription factors have been documented to function in a cell cycle-dependent manner [1] . We noticed that a putative E2F-binding sequence (TTTCGCGC) [23] was located at 227 to 220 base pairs from the transcription initiation site of Arhgap11a. Chromatin immunoprecipitation (ChIP) experiments demonstrated the direct association of E2F1 with that region ( Figure 2G ), which may be involved in the cell cycle-dependent transcriptional activation of this locus. A luciferase reporter assay showed E2F1-dependent transcriptional activation of the Arhgap11a promoter, which was blocked by association with the Rb protein ( Figure 2H ), suggesting the possible role of E2F/Rb pathways in the transcriptional regulation of Arhgap11a. We fully realize the involvement of other transcriptional factors since Arhgap11a was substantially expressed also in G1 phase ( Figure 2D ), although we can assume Rb/E2F pathway would be at least responsible for the increase in Arhgap11a expression in S phase.
ARHGAP11A is a GTPase-accelerating protein for Rho, but not for Rac or Cdc42, and inhibits Rho-dependent cellular phenomena ARHGAP11A had already been cloned and listed in an NCBI database, but its molecular function had not yet been characterized. Notably, it was unclear whether its putative GAP domain indeed exerts a GTPase-accelerating effect. To determine its function, we isolated Halo-tagged ARHGAP11A (or Halo-Tag only as a control) expressed in HEK293 cells ( Figure 3A) , and incubated it in vitro with several Rho family proteins, such as RhoA, Rac1, and Cdc42 ( Figure 3B ). In this assay, we measured GAP activity by detecting inorganic phosphate released due to GTP hydrolysis of Rho proteins [24] . This cell-free in vitro assay showed that ARHGAP11A greatly accelerated GTP hydrolysis of RhoA, but not that of Rac1 or Cdc42 ( Figure 3B ). The amounts of active forms of Rho family proteins were also assessed by pulldown assay with GST-Rhotekin (for Rho) or GST-CRIB (for Rac and Cdc42) in HEK293 cells [25] . Transfection of ARHGAP11A reduced the amounts of active RhoA, RhoB, and RhoC, but not of Rac1 or Cdc42 ( Figure 3C ). We also confirmed that this RhoGAP activity was essentially abolished when its putative GAP domain was deleted ( Figure 3D ). These results clearly confirm that ARHGAP11A is a GAP specific for Rho, but not for Rac or Cdc42, whose effect is mediated by its predicted GAP domain.
Active RhoA has been shown to stimulate focal adhesion and stress fiber formation by the activation of Rho-associated protein kinase (ROCK) and/or mDia ( Figure 4A ) [26] . Concordantly, exogenous expression of constitutively active RhoA (RhoA-Q63L) [27] in HCT116 cells induced aberrant increases in Factin stress fiber and focal adhesion formation, visualized by means of paxillin aggregates ( Figure 4B ). In contrast, suppression of Rho activity by CT04 (1 mg/ml), a potent Rho inhibitor [28] , reduced the formation of stress fibers and focal adhesions ( Figure 4C ). Under these experimental conditions, additional expression of ARHGAP11A significantly inhibited the formation of both F-actin stress fibers ( Figure 4D , middle panel, and 4E) and focal adhesions ( Figure 4D , right panel, and 4F). Expression of ARHGAP11A also reduced the level of phosphorylated myosin light chain (pMLC) ( Figure S7 ). In summary, ARHGAP11A, as a RhoGAP, suppressed Rho-dependent phenomena, such as focal adhesion and stress fiber formation, in HCT116 cancer cells. We also confirmed the function of ARHGAP11A in HeLa cells ( Figure 4G-I ).
ARHGAP11A stimulates cancer cell motility by enhancing Rac activity
Cell motility is known to be reciprocally regulated by diverse Rho family small G proteins [29] . Whereas active RhoA (or Rho or RhoC) stabilizes cytoskeletons by enhancing stress fiber and focal adhesion formation, activation of Rac1 (or Cdc42) makes cells flexible and mobile, leading to the formation of lamellipodia or filopodia [29] . The activities of the counteracting proteins RhoA and Rac1 are mutually controlled [30] , and inhibition of one results in the relative augmentation of the other ( Figure 5A ). Here, by using Raichu-Rac1, a FRET-based biosensor of Rac1 activity at the single-cell level [31, 32] , we examined Rac1 activity in HCT116 cells. Rac1 activity was significantly higher in ARHGAP11A-expressing cells compared to mock-transfected (transfected with Halo-Tag only) or non-transfected cells ( Figure 5 B and C), suggesting the mechanism by which the suppression of Rho activity leads to counter-activation of Rac1 at the single-cell level. Similar ARHGAP11A-mediated activation of Rac1 was also observed in HeLa cells ( Figure S8 ).
Next, we examined the effect of Rho inhibition by ARH-GAP11A on the control of cancer cell morphology and mobility. To analyze the morphological properties of cancer cells, we a utilized three-dimensional (3D) Matrigel culture system ( Figure 5 D and E) [33] . In results, over-expression of ARHGAP11A led to spindle-like shapes of HCT116 cells, representing an invasionprone phenotype. Similar morphogenic changes could also be observed when Rho-mediated signaling was inhibited by Y27632, a potent ROCK inhibitor [34] . We further measured the in vitro migratory properties of HCT116 cell in 3D Matrigel plates ( Figure 5 F and G) [35] , and concordantly, overexpression of ARHGAP11A or Y27632 treatment enhanced migration of HCT116 in vitro. On the other hand, strong inhibition of Rho activity by high concentration of Y72632 blocked the migration (data not shown). These results clearly suggest that adequate level of RhoA inhibition such as achieved by overexpression of ARHGAP11A enhanced migratory activity of HCT116 cancer cells. To analyze the function of ARHGAP11A, we generated HCT116 cell lines in which ARHGAP11A expression was stably reduced by shRNA (SH). Reduced expression of ARHGAP11A was confirmed at both the mRNA ( Figure 6A ) and protein ( Figure 6B ) levels. A BrdU proliferation assay showed no differences between control and SH cells, suggesting that ARHGAP11A does not influence cell-intrinsic proliferation in vitro ( Figure 6C ). On the other hand, an in vitro cell invasion assay with a Matrigel plate showed that invasion ability was significantly reduced in SH cells ( Figure 6D ). Next we examined the role of ARHGAP11A in in vivo motility of inoculated cancer cells. By using intravital multiphoton imaging techniques, we showed that SH cells were less motile than control cells in subcutaneously inoculated tumors, clearly demonstrating that ARHGAP11A regulates the motility of HCT116 cancer cells in vivo ( Figure 6E , Movie S4). We also found that SH cells were less able to migrate out from blood vessels than were control cells during extravasation of blood-resident cancer cells ( Figure 6F ). Finally, we investigated the role of ARHGAP11A in tumor expansion in vivo ( Figure 6G ). ARHGAP11A-knockdown SH cells exhibited less progression at day 28 compared with wild-type cells (SH#1, 6.4760.33 mm; SH#2, 6.6660.32 mm; wild-type, 9.7660.82 mm; and SH control, 9.3860.97 mm).
Next, we evaluated the potential of ARHGAP11A as a novel therapeutic target for inhibition of cancer progression. Subcutaneously implanted tumors were subjected to local injection of a siRNA targeting Arhgap11a or a scrambled control siRNA ( Figure 6H ). siRNAs were conjugated to atelocollagen to facilitate their introduction into target cells [36, 37] . We confirmed that (Table S1 ) (P.0.05). Of them, Arhgap11a was highly ranked, and all three probes for Arhgap11a were among the top-ranked probes for RhoGAPs. The three probes were specific for the indicated potions of the Arhgap11a mRNA (left). Figure S9 ), although we could not exclude the possibility that siRNAs against ARHGAP11A may be taken up by and act on the stromal cells surrounding the tumors. In vivo siRNA treatment significantly reduced tumor expansion (14716238.5 mm for scrambled siRNA, 422.1644.5 mm for siRNA#1, and 717.66162.7 mm for siRNA#2 at day 28), suggesting that ARHGAP11A is a promising therapeutic target for the treatment of invasive tumors ( Figure 6J ). Blockade of Arhgap11a would therefore be a conceptually novel anti-cancer therapy that would be expected to inhibit cancer cell mobilization and invasion into surrounding tissues.
Enhanced expression of ARHGAP11A in surgically resected human colorectal cancers Next, we investigated the clinical relevance of ARHGAP11A in human colon cancers in situ. Histological analyses of surgically dissected human colon cancer samples showed the preferential expression of ARHGAP11A at invasion sites ( Figure S10 ), an expression pattern resembling that of GMNN ( Figure S2 ). We also analyzed the expression of ARHGAP11A in clinical samples, including 74 colorectal cancers and five non-cancer mucosal tissue samples, using cDNA microarrays [35] . Expression of key molecules was assessed by qPCR, the results of which were reasonably correlated with the microarray data ( Figure S11 ). To ensure the specificity of the analyses, target regions (cancers or normal tissues) were collected by laser capture microdissection [38] . Relative expression of ARHGAP11A was significantly higher in tumors than in normal tissues ( Figure 7B ). Comparison with data on clinical disease stage (UICC-TNM; Union International Centre le Cancer-Tumor Node Metastasis) [39] demonstrated a stepwise increase in ARHGAP11A expression during the progression of T factors from T1 (tumors limited to the submucosa) to T3 (tumors penetrate the propria muscularis expression of Arhgap11a during progression of the cell cycle from G1 to S/G2/M. Fucci-red (mKO2)-positive HCT116 cells were sorted using a FACSAria cell sorter and were cultured for the indicated periods of time. Flow cytometry analyses (upper) and ratios of Fucci colors (left) are shown for each time point. (Right) Relative expression of Arhgap11a was examined by qPCR (n = 6). Data were analyzed by one-way ANOVA (p = 0.0001) and Bonferroni's multiple comparison test (*** p,0.01). (F) Cell cycle-dependent Arhgap11a expression in various human colon cancer cell lines. Fucci was introduced into different human colon cancer cell lines (HCT116, DLD1, HT29, and KM12SM). In all of the cell lines, Arhgap11a expression was significant higher in S/G2/M (green) than in G1 cells (red). (G) A chromatin immunoprecipitation (ChIP) assay with an anti-E2F1 antibody showed that E2F1 bound to the putative E2F-binding site in the Arhgap11a promoter (n = 3). (H) Luciferase reporter assay of the Arhgap11a promoter region (2500 bp), including the E2F-binding site (GTTTCGCGC) at 220 bp from the transcription starting point. Co-transfection with E2F1 enhanced transcriptional activity, whereas simultaneous expression of Rb blocked it. Values for luciferase activity were normalized across each experiment and, to control for differences in transfection efficiency, to b-galactosidase. doi:10.1371/journal.pone.0083629.g002 and reach the outermost layers) ( Figure 7C ). These results strongly suggest that up-regulation of ARHGAP11A would be conducive to increased mobility and invasiveness of human colon cancer cells in patients.
We re-analyzed microarray data deposited in the NCBI Gene Expression Omnibus (GEO) database using the NextBio data mining framework [40] and found that ARHGAP11A was upregulated in colorectal cancer tissues in eight of ten datasets ( Figure S12 ) [41] . Moreover, ARHGAP11A was up-regulated in various cancer tissues other than colorectal cancers, including glioblastoma, lung cancer, breast cancer, gastric cancer, hepatocellular carcinoma and pancreatic cancers ( Figure S13 ). In summary, ARHGAP11A, a cell cycle-dependent, mobilitycontrolling RhoGAP, is one of the most remarkable RhoGAP proteins in that it is associated with diverse epithelial cancer cell lines.
Discussion
The results of this study present several significant aspects. First of all, it is surprising that cell mobility and thus cancer invasiveness are critically linked to the cell cycle via the action of ARHGAP11A. We now know that the cell cycle is not simply a cycle of cell division but also the basic machinery for regulation of diverse cellular events such as mobilization. Notably, we identified ARHGAP11A as a regulator of cell cycle-dependent motility. We found that expression of ARHGAP11A is altered in a cell cycle-dependent manner and ARHGAP11A may be one of the target genes of E2F1 which activates transcription in cell cycle-related fashion. On the other hand, we do not currently know the mechanisms by which ARHGAP11A is up-regulated in cancers. Nevertheless, it has been known that Rb, a tumor suppressor factor, is functionally inactivated in various cancers, leading to aberrant activity of E2Fs [22] , which may result in enhanced expression of ARHGAP11A, although we cannot exclude the possibility that there are several other unidentified mechanisms to be involved. Additionally, we found that ARHGAP11A was modestly expressed in highly proliferative regions of normal mucosal tissues ( Figure S6 ). We believe that this is a novel concept, not only in cancer biology but also in the broader research field of cell biology.
Recently, several reports have demonstrated possible direct connection between various canonical mediators for cell cycle progression and cellular mobility [42] [43] [44] . For instance, p27, a cyclin-dependent kinase inhibitor (CKI), was shown to interfere with Rho guanine nucleotide exchange factor (GEF) by binding to RhoA [43] , while p21, another CKI, inhibits a Rho kinase, ROCK [44, 42] . On the other hand, RhoA was also reported to be associated with G1-S phase through transcriptional regulation of CKIs and cyclin D [45] , although these were not fully demonstrated with their molecular mechanism and physiological significance in vivo The present study, presenting ARHGAP11A as a cell cycle-dependent mobility-controlling molecule, exhibits a comprehensive example underlying the critical coupling between cell proliferation and migration.
Cell cycle-dependent expression control of ARHGAP11A and the resultant cell cycle-dependent mobility changes were less prominent when cells were cultured in vitro (unpublished observation), suggesting the particular significance of this regulatory mechanism for cancer cell expansion in in vivo environments. In contrast, one previous report showed that basal motility of cells was reduced in the late G2 phase compared to G1 [46] , which likely reflects preparation for cytokinesis, although the motility data were recorded in vitro and are not directly comparable to our in vivo analyses of cell motility.
A recent report showed that ARHGAP11A expression is increased and translocated to nucleus upon DNA damage in human glioblastoma [47] . And then, ARHGAP11A induces cell cycle arrest and apoptosis by binding and activating p53. The author indicated that some other ARHGAPs also control transcriptional activity of p53. Therefore, they consider that down-regulation of ARHGAPs in cancer associates with malignant phenotypes. However, we revealed that ARHGAP11A was upregulated in various cancers including glioblastoma, whereas almost ARHGAP isoforms were down-regulated. In fact, we showed that ARHGAP11A promotes migration and invasion of cancer cells, by inhibition RhoA and resultant counter-activation of Rac1.
Regulation of cancer cell mobility by Rho family proteins has been investigated extensively. There is abundant published evidence showing the critical role of Rho signaling, including that mediated by ROCK, on cancer cell invasion and metastasis [26, 48] . We also showed that strong inhibition of RhoA signaling rendered cells deformed and inhibited mobilization, although excessive activation of RhoA signaling (such as by RhoA-Q63L) signaling by expression of constitutive active RhoA (Q63L) made the cells too rigid ( Figure 4B ). In this study, we showed that adequate inhibition of Rho activity, by the expression of ARHGAP11A, a RhoGAP specific for RhoA, enhanced mobilization, suggesting the significance of 'fine tuning' of Rho activation tone. Furthermore, ARHGAP11A induced mobilization by counter-activation of Rac1, which is concordant with previous reports showing that the inhibition of Rho signaling led to morphological changes and mobilization via activation of Rac1 [49] . ARHGAP11A-high Fucci-green cells seemed to exhibit streaming-like migration with elongated shapes during extravasation, which may also be consistent with a previous report that elongated movement is mediated mainly by Rac1 [21, 50] .
Many researchers have been so far extensively studying on novel cancer treatments targeting invasion and/or metastasis. Focal adhesion kinase (FAK) has been fully investigated as a promising target because it is highly expressed in metastatic cancers and has been shown to be involved in their various features including tumor growth, invasion, metastasis and angiogenesis [51] . In fact, FAK kinase inhibitors had already been tried clinically, although these approaches was halted because of their off target effects derived from multiple consensus sequences in the kinase domain. In addition, a recent report shows that intermediate decrease in FAK expression (with FAKheterozygous allele), or incomplete inhibition by a low dose of pharmacological FAK inhibitor unexpectedly enhanced angiogenesis and tumor growth [52] . Matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, are another potential therapeutic target to invasion/metastasis, and also epithelial-mesenchymal transition (EMT) [53] . MMP inhibitors have been rapidly developed for therapeutic use, although the clinical trials have been withdrawn. This was because each MMPs have distinct, sometimes opposite, effects on tumor angiogenesis, and lack of isoform specific inhibitors rather increased the occurrence of malignancy. Here, we propose that ARHGAP11A may be a good novel candidate as a target against invasive cancers, namely blocking cancer cell progression by inhibiting invasive properties. Because of its oncostatic nature, this therapy may not be used alone. Nevertheless, we detected increased expression of ARHGAP11A in highly invasive tumor ( Figure S13 ){Kupershmidt, 2010 #428}, and this therapy would therefore be useful for treating highly invasive cancers, chief among them glioblastoma and pancreatic cancer, for which there are currently limited therapeutic approaches. Furthermore, ARHGAP11A is specifically increased in a wide array of cancers, compared as other ARHGAP family members ( Figure S12 ), suggesting the possibility that we could develop therapeutically effective inhibitors with less adverse effects. Consequently, ARHGAP11A, a RhoGAP preferentially expressed in invasive human cancers, may become a promising target for cancer therapy.
Materials and Methods
Ethics Statement
All animal experiments were performed with the approval of the Animal Experiments Committee of Osaka University (permission number: IFReC-AP-H21-01-7). All surgery was performed under isoflurane anesthesia, and all efforts were made to minimize suffering. Clinical tissue samples for analyses were obtained with written informed consent, under the protocol approved by the Osaka University Research Ethic Committee.
Quantitative real-time RT-PCR and protein analysis
Quantitative real-time PCR, preparation of cell lysates, and Western blotting were performed according to standard protocols. The primers used are listed in Table S2 . The antibodies used for Western blotting are listed in Table S3 .
Lentiviral transfection and stable cell sorting EGFP (pEGFP-C1, Clontech), DsRed2 (pDsRed2-C1, Clontech), mAG-hGem(1/110) and mKO2-hCdt1(30/120) (provided by Dr. Miyawaki, RIKEN-BSI, Japan) were cloned into the CSII-EF-MCS vector (provided by Dr. Miyoshi, RIKEN-BRC, Japan) and transfected into HEK293T cells with packaging plasmids [54] . Stable transformants were selected using a FACSAria cell sorter (BD Biosciences). EGFP and Fucci-green (mAG), and DsRed2 and Fucci-red (mKO2), were excited by 488-nm laser lines, and their emission was detected with 530/30BP and 585/42BP filters, respectively.
Establishment of knockdown cell lines
MISSION shRNA plasmids for human ARHGAP11A (Table S4), a scrambled control shRNA, and lentiviral packaging mix were purchased from Sigma. Lentivirus-mediated transfection of shRNAs was performed according to the manufacturer's instructions.
Chromatin immunoprecipitation (ChIP) analysis
ChIP was performed essentially as described previously [55] with an anti-human E2F1 polyclonal antibody (sc-251x, Santa Cruz) or a control IgG (H-270, Santa Cruz). The primers used are listed in Table S5 .
Purification of ARHGAP11A
Purification of the Halo-tag control and ARHGAP11A were performed according to the manufacturer's instructions. Briefly, HEK293 cells were transfected with control and ARHGAP11A Halo-tag expression vectors. Two days after transfection, transfected cells were collected and lysed with a lysis buffer. The resulting lysates were added to HaloLink Resin (Promega) and incubated for 6 h at 4uC with constant mixing. The resin was washed three times, and Halo-ARHGAP11A was cleaved by HaloTEV protease (Promega). After centrifugation, the supernatants were collected. Purified proteins were validated by Western blotting using an anti-ARHGAP11A antibody (Table S3 ).
In vitro RhoGAP assay
A RhoGAP assay (Cytoskeleton) was performed according to the manufacturer's instructions. Briefly, 9 ml of purified ARH-GAP11A (0.68 mg/ml) was added to reaction buffer and 5 ml of a small GTPase protein (RhoA, Rac1 or Cdc42, 0.78 mg/ml) and incubated with 10 ml of 800 mM for 20 min at 37uC. Then, 120 ml of CytoPhos reagent (Cytoskeleton) was added for 10 min to determine the amount of phosphate generated by the hydrolysis of GTP. The absorbance of each sample at 650 nm was read.
Pull-down activity assays of Rho, Rac, and Cdc42
Activities of Rho, Rac, and Cdc42 were measured using glutathione-S-transferase (GST)-CRIB and GST-Rhotekin, as described previously [25] . For assays, 24 h after transfection of HEK293 cells with Halo-ARHGAP11A or Halo-control vector (100-mm-diameter dish), the cells were lysed in 400 ml of a lysis buffer containing 15 mg of GST-CRIB (for Rac and Cdc42) or GST-Rhotekin (for Rho assays). The lysates were centrifuged at 20,0006g for 10 min, and the resulting supernatants were then incubated with glutathione-Sepharose (20 ml) for 1 h at 4uC. Glutathione-Sepharose was precipitated by centrifugation, and the bound proteins were probed with anti-Rac1, anti-Cdc42, anti-RhoA, anti-RhoB, and anti-RhoC antibodies.
Immunocytochemistry
Cells were grown in incubation chambers coated with BioCoat collagen I (BD Biosciences). When necessary, Halo-tag was labeled with Halo-tag Oregon green ligand (Promega) according to the manufacturer's protocol. Cells were fixed for 10 min at room temperature in PBS containing 4% (w/v) paraformaldehyde and were then permeabilized in PBS containing 0.5% (w/v) Triton X-100 and 2 mg/ml BSA for 10 min. The cells were incubated with primary antibodies, and then labeled with secondary antibodies. All images were taken with an A1 confocal microscope (Nikon). For quantification of paxillin number and F-actin mean intensity, transfected cells were imaged for each condition. Images of transfected cells were acquired using the same parameters, without automatic scaling and gain adjustment, to avoiding pixel saturation. In all cases, the mean F-actin fluorescence intensity over the whole cell area was measured using the commercially available software NIS-Elements (Nikon) ( Figure S14 ). Paxillin numbers were counted using an analysis tool, ''Object counter'', in NIS-Elements
FRET imaging of Rac1 activity
FRET images were obtained and processed using essentially the same conditions and procedures reported previously [31] . Briefly, HCT116 cells expressing Raichu-Rac1 (FRET Rac1 biosensor) were generated by transposon-mediated gene transfer as described previously [32] . Stable transformants were selected using a FACSAria cell sorter (BD Biosciences). Forty-eight hours after HCT116 cells expressing Raichu-Rac1 were transfected with Halo-control or Halo-ARHGAP11A vector, transfected cells were labeled with Halo-tag TMR ligand (Promega) according to the manufacturer's instructions. Cells were imaged with an inverted microscope (FLUOVIEW FV1000 system; Olympus, Tokyo, Japan) equipped with a 606 objective lens (Olympus). FRET and TMR ligand images were taken sequentially using two different setups. A 440-nm or 559-nm diode laser was used as the excitation laser for the FRET or TMR ligand, respectively. The following setups were used for imaging studies: FRET, DM405-440/515, SDM510; TMR ligand, DM405/488/ 559, BA575-675. After background subtraction, FRET ratio images were created using the MetaMorph software (Universal Imaging, West Chester, PA), and were visualized in the intensitymodulated display mode. In this display mode, eight colors from red to blue are used to represent the FRET ratio (YFP/CFP), with the intensity of each color indicating the mean intensity of YFP and CFP.
3D Matrigel culture
To analyze 3D epithelial morphogenesis in Matrigel (BD Biosciences), 40 ml of growth factor-reduced Matrigel was mounted on a round coverslip and incubated at 37uC for 30 min to solidify the gel. HCT116 cells (2610 4 ) suspended in 1 ml of growth medium containing 2% Matrigel (v/v) and 10 ng/ml EGF (R&D Systems, Minneapolis, MN, USA) were added to solid Matrigel and incubated for a further 48 h [33] .
Matrigel invasion assay
Equal numbers of Matrigel-coated and control (uncoated) inserts were prepared for each experiment. HCT116 cells (1.0610 5 cells/ml) were suspended in DMED medium containing EGF (10 ng/ml). Y27632 was added in some experiments. An aliquot of cell suspension (5.0610 4 cells in 0.5 ml) was added to each 24-well chamber. DMED containing 10% FBS and EGF was added to each well of the 24-well plate as a chemoattractant. After incubation of invasion plates at 37uC in a 5% CO 2 atmosphere for 36 h, non-migrating cells were removed with a cotton swab. The migrated cells on the lower surface of the membrane were stained with Diff-Quik. Stained cells were counted in three fields in triplicate. Invasion ratio was calculated as follows: Invasion index = mean number of cells migrating through the Matrigel matrix insert membrane/mean number of cells migrating through the uncoated insert membrane.
Intravital multiphoton imaging of cancer cells
Intravital imaging was performed using protocols described previously with modifications [7] . To create subcutaneous or colon tumor models, HCT116 cells were injected into the subcutaneous or cecum tissue of immunocompromised NOD/ SCID mice 5 weeks before observation [12] . Mice were anesthetized with isoflurane (2.0%, vaporized in air). Tumor masses were observed with an inverted multiphoton microscope (A1R-MP, Nikon), driven by a Chameleon Vision II Ti:Sapphire laser (Coherent) tuned to 940 nm and inverted microscopes equipped with multi-immersion objectives (CFI-Plan-Fluor, 20X/ N.A. 0.75, Nikon). To detect mAG (Fucci-green), mKO2 (Fuccired), and second harmonic generation (SHG) emission signals, 500/50-nm, 561/50-nm, and 440/50-nm band-pass filters were used, respectively. Raw imaging data were processed with Imaris (Bitplane) with a Gaussian filter for noise reduction. Automatic 3D object tracking with Imaris Spots was aided by manual correction to retrieve spatial cell co-ordinates over time.
Extravasation model of cancer cells
Under anesthesia, an arc-shaped incision was made in the abdominal skin of nude mice according to previous report [56] . The connective tissue between skin and abdominal wall was separated to free the skin flap without injuring the epigastrica cranialis artery and vein with 29G needle and 1 ml syringe. The skin flap was spread and fixed on the flat stand. A total of 1610 5 cancer cells embedded with solution containing matrigel (25 ml) and complete medium (25 ml) were injected into the epigastrica cranialis vein. The skin flap was sewed and closed until imaging. When the imaging was performed, the skin flap was re-opened, spread and fixed at the imaging stage for intravital imaging. The inside surface of the skin flap was imaged.
In vivo siRNA treatment HCT116 cells (5. 0610 6 ) were injected into subcutaneous tissues, and the resulting tumors were treated with siRNAs targeted to ARHGAP11A (Table S6 ) or a scrambled control siRNA, together with atelocollagen (AteloGene, Koken), 1 week after implantation. A 0.2-ml volume of siRNA solution (30 mmol/ L in 0.5% (v/v) atelocollagen) was injected directly into tumors. Injected siRNAs were shown to remain stable in vivo for at least 1 week when supported by atelocollagen [36, 37] .
Fucci-signal-based microarray analysis
Two implanted tumors of HCT116 cells expressing Fucci were excised from two NOD/SCID mice. Then, each tumor was minced with a razor blade and treated with dispase and collagenase. Each sample was processed by a pipetting procedure and DNase treatment. Each sample was sorted into Fucci-green and -red cells. 1.0-2.0610 5 cells were collected from each sample. mRNA (600-1500 ng in 30 ml of distilled water) was extracted from each sample using an RNeasy mRNA purification kit (Qiagen). Microarray analysis was performed as described previously [57] . The fold-change values shown in the figures and tables are ratios of normalized values.
Clinical sample microarrays
Tissues from 74 colorectal cancers and five normal colorectal tissue samples were obtained during surgery at Kyushu University Hospital, Beppu and its affiliated hospitals. Written informed consent was obtained from all patients and the study protocol was approved by the local ethics committee. Resected cancer tissues were sectioned and sampled by laser capture microdissection (LMD6000, Leica) [38] , and microarray analyses were performed as described previously [35] . Primers used for qPCR analyses to confirm the expression of key molecules are listed in Table S7 ).
Statistical analysis
Two-tailed Mann-Whitney U-tests, Kruskal-Wallis tests, and Dunnett's test were used to calculate p-values for skewed distributions. For Gaussian-like distributions, two-tailed Student's t-tests, one-way ANOVA, and Bonferroni's multiple comparison tests were used. Two-way ANOVA was used for implanted tumor size analysis.
Accession numbers
Microarray data from Fucci-green/red HCT116 and from human colorectal cancer specimens are available through the NCBI GEO database [accession numbers: GSE34940 (for Fucci) and GSE35279 (for human sample)]. Datasets used for reanalysis were listed in Table S8 . Table S7 ). Correlations between relative levels in microarray and qPCR analyses were determined. The graphs show regression lines (solid line) and 95% confidence intervals (break line). The correlation coefficients for Arhgap11a, Geminin, Hmgb2, Opi5, and Top2a were 0.5154, 0.5930, 0.4559, 0.4258, and 0.3920, respectively. (TIF) Figure S12 Analyses of ARHGAP family protein expression in primary human colon cancer datasets. The correlation between the ARHGAP family and human colon cancer was determined using the NextBio data mining framework (http://www.nextbio. com). Nine previous microarray studies and our own findings, in terms of the comparison of human primary colon cancers and normal tissues, were included. Fold changes compared to normal tissues are shown in each graph. ARHGAP11A fold changes were elevated in 8 of 10 studies. Gene Expression Omnibus (GEO) accession numbers (NextBio ID) for these studies were: 1, our data; 2, GSE10972_1; 3, GSE20916_3; 4, GSE28000_GPL4133_2; 5, GSE21815_1; 6, GSE23878_1; 7, GSE18105_1; 8, GSE22598_1; 9, GSE25070_1; and 10, GSE31279_1 (Table S8) . (TIF) Figure S13 Analyses of ARHGAP11A in primary human cancer datasets. The correlations between ARHGAP11A and various human cancers were determined using the NextBio data mining framework (http://www.nextbio.com). Studies comparing human cancers and normal tissues were selected. Fold changes compared to normal tissues are shown in the graphs. GEO accession numbers (NextBio ID) for these studies are shown in Table S8 . (TIF) Figure S14 A computational method for measurement of Factin intensity and focal adhesions. (A) Transfected cells (arrowheads) were labeled with Halo-Tag Oregon Green ligand (green). F-actin was labeled with Alexa 568-phaloidin (red). The antipaxillin antibody (mouse monoclonal) was labeled with an Alexa 633-conjugated anti-mouse IgG antibody (blue). Regions containing transfected cells (green) were selected automatically and their areas (upper right) were measured using NIS-Elements. Then, the mean intensity of F-actin fluorescence in the whole cell area was measured (lower left) using the ''Automatic Measurement'' function in NIS-Elements. The focal adhesion area was defined as 2 mm 
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